Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -22.62% is 51% above its 5-year average of -46.38%, near the high end of its 5-year range (-90.40%–-7.01%).
59.57% above its 12-month average of -55.95%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -7.51%.
RETURN ON ASSETS (ROA)
-22.62%
RETURN ON ASSETS (ROA) AVG TTM
-55.95%
RETURN ON ASSETS (ROA) AVG 3Y
-57.94%
RETURN ON ASSETS (ROA) AVG 5Y
-46.38%
RETURN ON ASSETS (ROA) AVG 10Y
-44.57%
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+59.57%
CURRENT VS 3Y AVG
+60.96%
CURRENT VS 5Y AVG
+51.23%
CURRENT VS 10Y AVG
+49.25%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-29.12%
median of 627 covered companies
CURRENT VS SECTOR MEDIAN
+22.32%
vs the sector median at left
Corvus Pharmaceuticals, Inc.
Market Cap
$870.53M
Return on Assets (ROA)
-22.62%
TTM Avg
-55.95%
3Y Avg
-57.94%
5Y Avg
-46.38%
Market Cap
$887.93M
Return on Assets (ROA)
55.85%
TTM Avg
-44.25%
3Y Avg
-43.62%
5Y Avg
-43.05%
Market Cap
$847.73M
Return on Assets (ROA)
-23.15%
TTM Avg
-12.59%
3Y Avg
-25.36%
5Y Avg
-32.38%
Market Cap
$894.80M
Return on Assets (ROA)
8.09%
TTM Avg
-0.64%
3Y Avg
-8.03%
5Y Avg
-4.54%
Market Cap
$838.16M
Return on Assets (ROA)
-24.96%
TTM Avg
-29.43%
3Y Avg
-70.30%
5Y Avg
-70.30%
Market Cap
$830.70M
Return on Assets (ROA)
-78.30%
TTM Avg
-72.68%
3Y Avg
-105.45%
5Y Avg
-105.45%
Market Cap
$915.13M
Return on Assets (ROA)
4.06%
TTM Avg
3.72%
3Y Avg
3.23%
5Y Avg
2.82%
Market Cap
$821.00M
Return on Assets (ROA)
-32.46%
TTM Avg
-61.56%
3Y Avg
-55.11%
5Y Avg
-72.90%
Market Cap
$924.43M
Return on Assets (ROA)
-45.94%
TTM Avg
-39.23%
3Y Avg
-37.58%
5Y Avg
-117.41%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Corvus Pharmaceuticals, Inc. (CRVS) | $870.53M | -22.62% | -55.95% | -57.94% | -46.38% |
| Arbutus Biopharma Corp (ABUS)vs › | $887.93M | 55.85% | -44.25% | -43.62% | -43.05% |
| Monte Rosa Therapeutics, Inc. (GLUE)vs › | $847.73M | -23.15% | -12.59% | -25.36% | -32.38% |
| Bioventus Inc. (BVS)vs › | $894.80M | 8.09% | -0.64% | -8.03% | -4.54% |
| Beta Bionics, Inc. (BBNX)vs › | $838.16M | -24.96% | -29.43% | -70.30% | -70.30% |
| Alumis Inc. (ALMS)vs › | $830.70M | -78.30% | -72.68% | -105.45% | -105.45% |
| HealthStream, Inc. (HSTM)vs › | $915.13M | 4.06% | 3.72% | 3.23% | 2.82% |
| Jade Biosciences, Inc. (JBIO)vs › | $821.00M | -32.46% | -61.56% | -55.11% | -72.90% |
| MoonLake Immunotherapeutics (MLTX)vs › | $924.43M | -45.94% | -39.23% | -37.58% | -117.41% |
| CeriBell, Inc. (CBLL)vs › | $929.91M | -39.67% | -22.62% | -34.56% | -34.56% |
ROA
-22.6%
ROE
-24.0%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -21.49% |
| 2024-12-31 | -90.40% |
| 2023-12-31 | -59.34% |
| 2022-12-31 | -60.53% |
| 2021-12-31 | -39.51% |
| 2020-12-31 | -7.01% |
| 2019-12-31 | -55.80% |
| 2018-12-31 | -39.70% |
| 2017-12-31 | -58.73% |
| 2016-12-31 | -25.95% |
| 2015-12-31 | -31.83% |
| 2014-12-31 | -1.40% |
